Report Code: CMI45054

Published Date: April 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 3.1%
24,158.2M
2023
24,907.1M
2024
32,783.2M
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Amgen Inc.
  • Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Cancer Supportive Care Drugs Market is expected to record a CAGR of 3.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 24,907.1 Million. By 2033, the valuation is anticipated to reach USD 32,783.2 Million.

The Cancer Supportive Care Drugs Market encompasses pharmaceuticals and therapies aimed at managing symptoms and side effects associated with cancer treatment. These drugs alleviate pain, nausea, anemia, and other adverse effects, enhancing patients’ quality of life during cancer therapy.

With the increasing prevalence of cancer globally and advancements in cancer treatment modalities, the demand for supportive care drugs continues to grow. This market also includes supportive care services, such as counselling and nutritional support.

Companies invest in research and development to innovate new drugs and therapies, contributing to the expansion and evolution of the Cancer Supportive Care Drugs Market.

Cancer Supportive Care Drugs Market – Significant Growth Factors

The Cancer Supportive Care Drugs Market presents significant growth opportunities due to several factors:

  • Increasing Cancer Incidence: The rising prevalence of cancer worldwide is a primary driver for the market. As cancer rates continue to escalate, the demand for supportive care drugs to manage treatment-related side effects such as pain, nausea, and anemia also increases.
  • Advancements in Cancer Treatment: Technological advancements in cancer treatment modalities, including chemotherapy, radiation therapy, and immunotherapy, have led to improved survival rates. However, these treatments often result in debilitating side effects, driving the need for supportive care drugs to enhance patients’ quality of life during treatment.
  • Aging Population: The aging population is more susceptible to cancer and its associated side effects. With a significant portion of the population aging globally, there is a corresponding increase in the demand for supportive care drugs to manage the symptoms and complications of cancer treatment in elderly patients.
  • Regulatory Support and Guidelines: Regulatory agencies and healthcare organizations have developed guidelines and protocols emphasizing the importance of supportive care in cancer treatment. Compliance with these guidelines drives the adoption of supportive care drugs and promotes their integration into standard cancer care protocols.
  • Expansion of Indications: There is an opportunity to expand the indications for supportive care drugs beyond oncology. With advancements in personalized medicine and targeted therapies, supportive care drugs may find applications in managing side effects associated with other chronic diseases, such as autoimmune disorders and infectious diseases.

Cancer Supportive Care Drugs Market – Mergers and Acquisitions

The Cancer Supportive Care Drugs Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Supportive Care Drugs Market include:

  • In 2022, Imugene, an Australian company, announced a clinical trial collaboration and supply agreement with Merck & Co., Inc. (MSD), to assess the safety and efficacy of Imugene’s HER-Vaxx in combination with MSD’s pembrolizumab (KEYTRUDA) in HER-2 positive gastric cancer patients.
  • In 2021, Bristol Myers Squibb reported that Idhifa, FDA-approved for relapsed or refractory AML with an IDH2 mutation, did not demonstrate improved survival outcomes in the same patient group when administered alongside optimal supportive care.
  • In 2022, Gamida Cell’s allogeneic cell therapy Omisirge received FDA approval, promising to enhance access to stem cell transplants and improve patient outcomes. This milestone marks a significant advancement in the field of cell therapy and offers hope for patients in need of transplantation.
  • In 2022, Guardant Health introduced the Shield test, a non-invasive blood-based screening method for detecting colorectal cancer. This test eliminates the need for sedation and dietary changes, offering a less painful and more convenient option. It detects early colorectal cancer signals in the bloodstream, enhancing early detection efforts.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Supportive Care Drugs Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Cancer Supportive Care Drugs Market Cancer Monoclonal Antibody Testing Market Cancer Monoclonal Antibodies Market
CAGR 3.1% (Approx) CAGR 7.6% (Approx) CAGR 8.2% (Approx)
USD 32,783.2 Million by 2033 USD 175.1 Billion by 2033 USD 231.4 Billion by 2033

Cancer Supportive Care Drugs Market – Significant Threats

The Cancer Supportive Care Drugs Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Regulatory Challenges: Stringent regulatory requirements and compliance standards pose challenges for drug approval and market entry. Delays in regulatory approvals or stringent safety and efficacy criteria may hinder the availability of new supportive care drugs, impacting market growth.
  • Patent Expirations: The expiration of patents for existing supportive care drugs can lead to increased competition from generic alternatives, resulting in pricing pressures and erosion of market share for branded medications. This can impact revenues and profitability for pharmaceutical companies operating in the supportive care drugs market.
  • Opioid Epidemic Concerns: Heightened scrutiny and regulatory restrictions surrounding opioid medications due to concerns over addiction, misuse, and overdose pose a significant threat to the supportive care drugs market. Increased regulations and prescribing limitations may restrict access to opioid-based supportive care therapies for cancer patients who require them.
  • Healthcare Cost Containment Measures: Cost-containment efforts by healthcare payers and institutions may lead to reimbursement challenges and pricing pressures for supportive care drugs. Reduced reimbursement rates or formulary restrictions can impact market access and uptake of novel supportive care treatments.
  • Competitive Landscape: Intense competition within the supportive care drugs market from established pharmaceutical companies and emerging biotech firms can pose challenges to market penetration and differentiation of products. Companies must invest in research and development to innovate new therapies and differentiate themselves from competitors to maintain market share and profitability.

Global Cancer Supportive Care Drugs Market 2024–2033 (By Mode of Administration)

www.custommarketinsight.com

Category-Wise Insights

By Drug Type

  • Antiemetics: Antiemetics are drugs used to prevent or alleviate nausea and vomiting commonly associated with cancer chemotherapy. Trends include the development of newer, more effective antiemetic agents and the integration of antiemetic therapy into comprehensive cancer treatment protocols to improve patient’s quality of life.
  • Erythropoietin Stimulating Agents: Erythropoietin stimulating agents are medications used to stimulate red blood cell production and treat anemia in cancer patients undergoing chemotherapy. Trends include the optimization of erythropoietin therapy protocols to minimize risks and improve outcomes, along with increased utilization of alternative anemia management strategies.
  • Bisphosphonates: Bisphosphonates are drugs that help prevent bone loss and reduce the risk of skeletal-related events in cancer patients with bone metastases. Trends include the development of next-generation bisphosphonates with improved efficacy and safety profiles, as well as the exploration of bisphosphonate use in adjuvant cancer therapy settings.
  • Granulocyte Colony-Stimulating Factors: Granulocyte colony-stimulating factors are medications used to stimulate the production of white blood cells and reduce the risk of febrile neutropenia in cancer patients undergoing chemotherapy. Trends include the development of long-acting formulations and biosimilars to enhance patient convenience and reduce treatment burden.
  • Opioids and Non-Opioids: Opioids and non-opioids are medications used for pain management in cancer patients. Trends include the development of novel opioid formulations with improved tolerability and abuse-deterrent properties, as well as the integration of non-opioid analgesics and multimodal pain management strategies to minimize opioid-related side effects and risks.
  • Others: This category encompasses various supportive care drugs used in cancer treatment, including corticosteroids, anti-inflammatory agents, growth factors, and nutritional supplements. Trends include the exploration of novel drug targets and treatment modalities to address specific symptoms and complications associated with cancer therapy, such as mucositis, neuropathy, and fatigue.

By Cancer Type

  • Breast Cancer: Cancer supportive care drugs for breast cancer encompass therapies targeting chemotherapy-induced nausea, bone health, and hormonal treatments’ side effects, including hot flashes. Trends include advancements in targeted therapies and hormone treatments, along with a focus on personalized medicine to manage treatment-related symptoms more effectively.
  • Lung Cancer: Supportive care drugs for lung cancer address symptoms such as chemotherapy-induced nausea, pain management, and management of respiratory complications. Trends include the development of targeted therapies and immunotherapies to alleviate treatment-related side effects and improve patients’ quality of life.
  • Prostate Cancer: Supportive care drugs for prostate cancer aim to manage symptoms such as bone pain, hormonal treatment side effects, and chemotherapy-induced nausea. Trends include advancements in hormonal therapies and bone health medications, along with increased utilization of targeted therapies and immunotherapies.
  • Colorectal Cancer: Supportive care drugs for colorectal cancer focus on managing side effects such as chemotherapy-induced nausea, diarrhea, and neuropathy. Trends include the development of targeted therapies and immunotherapies tailored to colorectal cancer patients, along with a growing emphasis on nutritional support and gastrointestinal symptom management.
  • Leukemia: Supportive care drugs for leukemia target symptoms such as chemotherapy-induced nausea, infections, and anemia management. Trends include advancements in targeted therapies and immunotherapies for leukemia patients, along with a focus on supportive care interventions to minimize treatment-related complications and improve outcomes.
  • Lymphoma: Supportive care drugs for lymphoma address symptoms such as chemotherapy-induced nausea, infections, and immune-related adverse events. Trends include the development of targeted therapies and immunotherapies specific to lymphoma subtypes, along with a growing focus on supportive care interventions to enhance patients’ quality of life during treatment.
  • Others: Supportive care drugs for other types of cancer encompass a broad range of therapies targeting chemotherapy-induced side effects, pain management, and supportive care interventions tailored to specific cancer types and patient needs. Trends include advancements in personalized medicine, targeted therapies, and supportive care interventions to address unmet needs across various cancer types.

Global Cancer Supportive Care Drugs Market 2024–2033 (By Distribution Channel)

www.custommarketinsight.com

Mode of Administration

  • Oral: Oral administration involves delivering supportive care drugs via the mouth, commonly in the form of tablets, capsules, or liquids. Trends include the development of oral formulations for chemotherapy-induced nausea, pain management, and anemia treatment, offering convenience and improved patient compliance in the Cancer Supportive Care Drugs Market.
  • Injectable: Injectable administration involves administering supportive care drugs through injections, typically intravenously or subcutaneously. Trends include the introduction of long-acting injectable formulations for chemotherapy-induced neutropenia, erythropoiesis-stimulating agents for anemia, and antiemetics for nausea and vomiting, providing rapid and targeted relief in the Cancer Supportive Care Drugs Market.
  • Topical: Topical administration involves applying supportive care drugs directly to the skin surface, often in the form of creams, gels, or patches. Trends include the development of topical analgesics for localized pain management, anti-inflammatory creams for skin reactions, and transdermal patches for continuous drug delivery, offering targeted relief with minimal systemic side effects in the Cancer Supportive Care Drugs Market.
  • Others: Other modes of administration in the Cancer Supportive Care Drugs Market encompass less common routes such as intramuscular injections, inhalation therapy, and rectal suppositories. Emerging trends include the exploration of novel delivery methods, including implantable devices and nanotechnology-based drug delivery systems, to enhance drug efficacy and patient comfort.

By Distribution Channel

  • Hospital Pharmacies: Hospital pharmacies dispense medications and supportive care drugs to inpatients and outpatients within hospital settings. Trends include the integration of electronic prescribing systems, medication management technologies, and clinical pharmacy services to optimize medication therapy and enhance patient safety in cancer care.
  • Retail Pharmacies: Retail pharmacies provide supportive care drugs and medications to patients for outpatient use. Trends include the expansion of oncology-focused pharmacy services, such as medication counseling, adherence programs, and specialty drug compounding, to meet the unique needs of cancer patients and improve treatment outcomes.
  • Online Pharmacies: Online pharmacies offer convenience and accessibility for cancer patients to access supportive care drugs and medications remotely. Trends include the increasing adoption of telemedicine platforms, digital prescription services, and medication delivery options, providing patients with greater flexibility and convenience in managing their cancer treatment and supportive care needs.
  • Specialty Clinics: Specialty clinics specialize in providing comprehensive care and supportive services to cancer patients, including medication management and supportive care interventions. Trends include the integration of multidisciplinary care teams, patient education programs, and survivorship services to address the complex needs of cancer patients throughout their treatment journey.
  • Others: This category may include alternative distribution channels such as infusion centers, ambulatory care clinics, and home healthcare providers that also dispense supportive care drugs and medications to cancer patients. Trends may vary depending on the specific healthcare setting and patient population served.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 24,907.1 Million
Projected Market Size in 2033 USD 32,783.2 Million
Market Size in 2023 USD 24,158.2 Million
CAGR Growth Rate 3.1% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Drug Type, Cancer Type, Mode of Administration, Distribution Channel and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Cancer Supportive Care Drugs Market – Regional Analysis

The Cancer Supportive Care Drugs Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, a key trend in the Cancer Supportive Care Drugs Market is the increasing adoption of targeted therapies and immunotherapy, driving demand for supportive care drugs to manage immune-related adverse events. Additionally, there’s a growing emphasis on personalized medicine, with the development of biomarker-driven supportive care interventions tailored to individual patient profiles.
  • Europe: In Europe, there’s a trend towards the integration of supportive care services into oncology care pathways, promoting multidisciplinary collaboration and patient-centered care. Furthermore, there’s a focus on expanding access to supportive care drugs through initiatives aimed at reducing healthcare disparities and improving affordability, enhancing patient outcomes and quality of life.
  • Asia-Pacific: The Asia-Pacific region is witnessing a surge in cancer incidence and increasing healthcare expenditure, driving market growth for supportive care drugs. Key trends include the adoption of innovative drug delivery technologies and the expansion of oncology-focused healthcare infrastructure to address the growing burden of cancer and improve access to supportive care interventions.
  • LAMEA (Latin America, Middle East, and Africa): In the LAMEA region, there’s a focus on addressing healthcare infrastructure challenges and improving access to supportive care drugs in underserved areas. Key trends include the development of partnerships between pharmaceutical companies, healthcare organizations, and government agencies to expand access to affordable supportive care interventions and enhance cancer care delivery.

Global Cancer Supportive Care Drugs Market 2024–2033 (By Million)

www.custommarketinsight.com

Competitive Landscape – Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Amgen Inc.
  • Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • GlaxoSmithKline plc
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New entrants into the Cancer Supportive Care Drugs Market, such as biotech startups and specialty pharmaceutical companies, are leveraging innovation and development to establish their presence. These players often focus on niche areas or novel drug delivery systems to address unmet needs in supportive cancer care.

Conversely, key players dominating the market, like Amgen, Roche, and Johnson & Johnson, maintain their leadership through extensive research capabilities, robust product portfolios, global market presence, and strategic collaborations with healthcare providers and advocacy organizations, ensuring widespread adoption and market dominance.

The Cancer Supportive Care Drugs Market is segmented as follows:

By Drug Type

  • Antiemetics
  • Erythropoietin Stimulating Agents
  • Bisphosphonates
  • Granulocyte Colony-Stimulating Factors
  • Opioids and Non-Opioids
  • Others

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Leukemia
  • Lymphoma
  • Others

By Mode of Administration

  • Oral
  • Injectable
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Cancer Supportive Care Drugs Market, (2024 – 2033) (USD Million)
    • 2.2 Global Cancer Supportive Care Drugs Market: snapshot
  • Chapter 3. Global Cancer Supportive Care Drugs Market – Industry Analysis
    • 3.1 Cancer Supportive Care Drugs Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Cancer Incidence
      • 3.2.2 Advancements in Cancer Treatment
      • 3.2.3 Aging Population
      • 3.2.4 Regulatory Support and Guidelines
      • 3.2.5 Expansion of Indications
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Drug Type
      • 3.7.2 Market Attractiveness Analysis By Cancer Type
      • 3.7.3 Market Attractiveness Analysis By Mode of Administration
      • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • Chapter 4. Global Cancer Supportive Care Drugs Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Cancer Supportive Care Drugs Market: Company Market Share, 2023
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Cancer Supportive Care Drugs Market – Drug Type Analysis
    • 5.1 Global Cancer Supportive Care Drugs Market Overview: By Drug Type
      • 5.1.1 Global Cancer Supportive Care Drugs Market Share, By Drug Type, 2023 and 2033
    • 5.2 Antiemetics
      • 5.2.1 Global Cancer Supportive Care Drugs Market by Antiemetics, 2024 – 2033 (USD Million)
    • 5.3 Erythropoietin Stimulating Agents
      • 5.3.1 Global Cancer Supportive Care Drugs Market by Erythropoietin Stimulating Agents, 2024 – 2033 (USD Million)
    • 5.4 Bisphosphonates
      • 5.4.1 Global Cancer Supportive Care Drugs Market by Bisphosphonates, 2024 – 2033 (USD Million)
    • 5.5 Granulocyte Colony-Stimulating Factors
      • 5.5.1 Global Cancer Supportive Care Drugs Market by Granulocyte Colony-Stimulating Factors, 2024 – 2033 (USD Million)
    • 5.6 Opioids and Non-Opioids
      • 5.6.1 Global Cancer Supportive Care Drugs Market by Opioids and Non-Opioids, 2024 – 2033 (USD Million)
    • 5.7 Others
      • 5.7.1 Global Cancer Supportive Care Drugs Market by Others, 2024 – 2033 (USD Million)
  • Chapter 6. Global Cancer Supportive Care Drugs Market – Cancer Type Analysis
    • 6.1 Global Cancer Supportive Care Drugs Market Overview: By Cancer Type
      • 6.1.1 Global Cancer Supportive Care Drugs Market Share, By Cancer Type, 2023 and 2033
    • 6.2 Breast Cancer
      • 6.2.1 Global Cancer Supportive Care Drugs Market by Breast Cancer, 2024 – 2033 (USD Million)
    • 6.3 Lung Cancer
      • 6.3.1 Global Cancer Supportive Care Drugs Market by Lung Cancer, 2024 – 2033 (USD Million)
    • 6.4 Prostate Cancer
      • 6.4.1 Global Cancer Supportive Care Drugs Market by Prostate Cancer, 2024 – 2033 (USD Million)
    • 6.5 Colorectal Cancer
      • 6.5.1 Global Cancer Supportive Care Drugs Market by Colorectal Cancer, 2024 – 2033 (USD Million)
    • 6.6 Leukemia
      • 6.6.1 Global Cancer Supportive Care Drugs Market by Leukemia, 2024 – 2033 (USD Million)
    • 6.7 Lymphoma
      • 6.7.1 Global Cancer Supportive Care Drugs Market by Lymphoma, 2024 – 2033 (USD Million)
    • 6.8 Others
      • 6.8.1 Global Cancer Supportive Care Drugs Market by Others, 2024 – 2033 (USD Million)
  • Chapter 7. Global Cancer Supportive Care Drugs Market – Mode of Administration Analysis
    • 7.1 Global Cancer Supportive Care Drugs Market Overview: By Mode of Administration
      • 7.1.1 Global Cancer Supportive Care Drugs Market Share, By Mode of Administration, 2023 and 2033
    • 7.2 Oral
      • 7.2.1 Global Cancer Supportive Care Drugs Market by Oral, 2024 – 2033 (USD Million)
    • 7.3 Injectable
      • 7.3.1 Global Cancer Supportive Care Drugs Market by Injectable, 2024 – 2033 (USD Million)
    • 7.4 Topical
      • 7.4.1 Global Cancer Supportive Care Drugs Market by Topical, 2024 – 2033 (USD Million)
    • 7.5 Others
      • 7.5.1 Global Cancer Supportive Care Drugs Market by Others, 2024 – 2033 (USD Million)
  • Chapter 8. Global Cancer Supportive Care Drugs Market – Distribution Channel Analysis
    • 8.1 Global Cancer Supportive Care Drugs Market Overview: By Distribution Channel
      • 8.1.1 Global Cancer Supportive Care Drugs Market Share, By Distribution Channel, 2023 and 2033
    • 8.2 Hospital Pharmacies
      • 8.2.1 Global Cancer Supportive Care Drugs Market by Hospital Pharmacies, 2024 – 2033 (USD Million)
    • 8.3 Retail Pharmacies
      • 8.3.1 Global Cancer Supportive Care Drugs Market by Retail Pharmacies, 2024 – 2033 (USD Million)
    • 8.4 Online Pharmacies
      • 8.4.1 Global Cancer Supportive Care Drugs Market by Online Pharmacies, 2024 – 2033 (USD Million)
    • 8.5 Specialty Clinics
      • 8.5.1 Global Cancer Supportive Care Drugs Market by Specialty Clinics, 2024 – 2033 (USD Million)
    • 8.6 Others
      • 8.6.1 Global Cancer Supportive Care Drugs Market by Others, 2024 – 2033 (USD Million)
  • Chapter 9. Cancer Supportive Care Drugs Market – Regional Analysis
    • 9.1 Global Cancer Supportive Care Drugs Market Regional Overview
    • 9.2 Global Cancer Supportive Care Drugs Market Share, by Region, 2023 & 2033 (USD Million)
    • 9.3. North America
      • 9.3.1 North America Cancer Supportive Care Drugs Market, 2024 – 2033 (USD Million)
        • 9.3.1.1 North America Cancer Supportive Care Drugs Market, by Country, 2024 – 2033 (USD Million)
    • 9.4 North America Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033
      • 9.4.1 North America Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033 (USD Million)
    • 9.5 North America Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033
      • 9.5.1 North America Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033 (USD Million)
    • 9.6 North America Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033
      • 9.6.1 North America Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033 (USD Million)
    • 9.7 North America Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033
      • 9.7.1 North America Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 9.8. Europe
      • 9.8.1 Europe Cancer Supportive Care Drugs Market, 2024 – 2033 (USD Million)
        • 9.8.1.1 Europe Cancer Supportive Care Drugs Market, by Country, 2024 – 2033 (USD Million)
    • 9.9 Europe Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033
      • 9.9.1 Europe Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033 (USD Million)
    • 9.10 Europe Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033
      • 9.10.1 Europe Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033 (USD Million)
    • 9.11 Europe Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033
      • 9.11.1 Europe Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033 (USD Million)
    • 9.12 Europe Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033
      • 9.12.1 Europe Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 9.13. Asia Pacific
      • 9.13.1 Asia Pacific Cancer Supportive Care Drugs Market, 2024 – 2033 (USD Million)
        • 9.13.1.1 Asia Pacific Cancer Supportive Care Drugs Market, by Country, 2024 – 2033 (USD Million)
    • 9.14 Asia Pacific Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033
      • 9.14.1 Asia Pacific Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033 (USD Million)
    • 9.15 Asia Pacific Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033
      • 9.15.1 Asia Pacific Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033 (USD Million)
    • 9.16 Asia Pacific Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033
      • 9.16.1 Asia Pacific Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033 (USD Million)
    • 9.17 Asia Pacific Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033
      • 9.17.1 Asia Pacific Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 9.18. Latin America
      • 9.18.1 Latin America Cancer Supportive Care Drugs Market, 2024 – 2033 (USD Million)
        • 9.18.1.1 Latin America Cancer Supportive Care Drugs Market, by Country, 2024 – 2033 (USD Million)
    • 9.19 Latin America Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033
      • 9.19.1 Latin America Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033 (USD Million)
    • 9.20 Latin America Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033
      • 9.20.1 Latin America Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033 (USD Million)
    • 9.21 Latin America Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033
      • 9.21.1 Latin America Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033 (USD Million)
    • 9.22 Latin America Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033
      • 9.22.1 Latin America Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 9.23. The Middle-East and Africa
      • 9.23.1 The Middle-East and Africa Cancer Supportive Care Drugs Market, 2024 – 2033 (USD Million)
        • 9.23.1.1 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Country, 2024 – 2033 (USD Million)
    • 9.24 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033
      • 9.24.1 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Drug Type, 2024 – 2033 (USD Million)
    • 9.25 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033
      • 9.25.1 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Cancer Type, 2024 – 2033 (USD Million)
    • 9.26 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033
      • 9.26.1 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Mode of Administration, 2024 – 2033 (USD Million)
    • 9.27 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033
      • 9.27.1 The Middle-East and Africa Cancer Supportive Care Drugs Market, by Distribution Channel, 2024 – 2033 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1 Amgen Inc.
      • 10.1.1 Overview
      • 10.1.2 Financials
      • 10.1.3 Product Portfolio
      • 10.1.4 Business Strategy
      • 10.1.5 Recent Developments
    • 10.2 F. Hoffmann-La Roche Ltd.
      • 10.2.1 Overview
      • 10.2.2 Financials
      • 10.2.3 Product Portfolio
      • 10.2.4 Business Strategy
      • 10.2.5 Recent Developments
    • 10.3 Johnson & Johnson
      • 10.3.1 Overview
      • 10.3.2 Financials
      • 10.3.3 Product Portfolio
      • 10.3.4 Business Strategy
      • 10.3.5 Recent Developments
    • 10.4 Merck & Co. Inc.
      • 10.4.1 Overview
      • 10.4.2 Financials
      • 10.4.3 Product Portfolio
      • 10.4.4 Business Strategy
      • 10.4.5 Recent Developments
    • 10.5 Pfizer Inc.
      • 10.5.1 Overview
      • 10.5.2 Financials
      • 10.5.3 Product Portfolio
      • 10.5.4 Business Strategy
      • 10.5.5 Recent Developments
    • 10.6 Novartis International AG
      • 10.6.1 Overview
      • 10.6.2 Financials
      • 10.6.3 Product Portfolio
      • 10.6.4 Business Strategy
      • 10.6.5 Recent Developments
    • 10.7 Bristol Myers Squibb Company
      • 10.7.1 Overview
      • 10.7.2 Financials
      • 10.7.3 Product Portfolio
      • 10.7.4 Business Strategy
      • 10.7.5 Recent Developments
    • 10.8 Eli Lilly and Company
      • 10.8.1 Overview
      • 10.8.2 Financials
      • 10.8.3 Product Portfolio
      • 10.8.4 Business Strategy
      • 10.8.5 Recent Developments
    • 10.9 Sanofi S.A.
      • 10.9.1 Overview
      • 10.9.2 Financials
      • 10.9.3 Product Portfolio
      • 10.9.4 Business Strategy
      • 10.9.5 Recent Developments
    • 10.10 Takeda Pharmaceutical Company Limited
      • 10.10.1 Overview
      • 10.10.2 Financials
      • 10.10.3 Product Portfolio
      • 10.10.4 Business Strategy
      • 10.10.5 Recent Developments
    • 10.11 Teva Pharmaceutical Industries Ltd.
      • 10.11.1 Overview
      • 10.11.2 Financials
      • 10.11.3 Product Portfolio
      • 10.11.4 Business Strategy
      • 10.11.5 Recent Developments
    • 10.12 AbbVie Inc.
      • 10.12.1 Overview
      • 10.12.2 Financials
      • 10.12.3 Product Portfolio
      • 10.12.4 Business Strategy
      • 10.12.5 Recent Developments
    • 10.13 AstraZeneca PLC
      • 10.13.1 Overview
      • 10.13.2 Financials
      • 10.13.3 Product Portfolio
      • 10.13.4 Business Strategy
      • 10.13.5 Recent Developments
    • 10.14 Bayer AG
      • 10.14.1 Overview
      • 10.14.2 Financials
      • 10.14.3 Product Portfolio
      • 10.14.4 Business Strategy
      • 10.14.5 Recent Developments
    • 10.15 GlaxoSmithKline plc
      • 10.15.1 Overview
      • 10.15.2 Financials
      • 10.15.3 Product Portfolio
      • 10.15.4 Business Strategy
      • 10.15.5 Recent Developments
    • 10.16 Others.
      • 10.16.1 Overview
      • 10.16.2 Financials
      • 10.16.3 Product Portfolio
      • 10.16.4 Business Strategy
      • 10.16.5 Recent Developments
List Of Figures

Figures No 1 to 40

List Of Tables

Tables No 1 to 102

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Amgen Inc.
  • Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • GlaxoSmithKline plc
  • Others

FAQs

The key factors driving the Market are Increasing Cancer Incidence, Advancements in Cancer Treatment, Aging Population, Regulatory Support and Guidelines, Expansion of Indications.

The “Antiemetics” category dominated the market in 2023.

The key players in the market are Amgen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Novartis International AG, Bristol Myers Squibb Company, Eli Lilly and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., AstraZeneca PLC, Bayer AG, GlaxoSmithKline plc, Others.

“North America” had the largest share in the Cancer Supportive Care Drugs Market.

The global market is projected to grow at a CAGR of 3.1% during the forecast period, 2024-2033.

The Cancer Supportive Care Drugs Market size was valued at USD 24,907.1 Million in 2024.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!